The controversial role of tumor necrosis factor α in fibrotic diseases

Arthritis and Rheumatism

Volumn 58, Issue 8, 2008, Pages 2228-2235

  Distler, Jörg H W ^a   Schett, Georg ^a   Gay, Steffen ^b   Distler, Oliver ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; MATRIX METALLOPROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR JUNB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ALLERGIC GLOMERULONEPHRITIS; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; COLLAGEN SYNTHESIS; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; ENZYME RELEASE; EXPERIMENTAL MODEL; FIBROBLAST; FIBROSIS; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY FIBROSIS; LUNG FIBROSIS; MEDIATOR; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS;

ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MICE; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49449088182     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23645     Document Type: Review

References (59)

1. Friedman SL, Bansal MB. Reversal of hepatic fibrosis - fact or fantasy? Hepatology 2006;43 Suppl 1:S82-8.
2. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006;69:213-7.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
4. Idriss HT, Naismith JH. TNFα and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000;50:184-95.
5. Beyaert R, Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity: what we do understand and what we do not. FEBS Lett 1994;340:9-16.
6. Watts AD, Hunt NH, Hambly BD, Chaudhri G. Separation of tumor necrosis factor α isoforms by two-dimensional Polyacrylamide gel electrophoresis. Electrophoresis 1997;18:1086-91.
7. Loetscher H, Steinmetz M, Lesslauer W. Tumor necrosis factor: receptors and inhibitors. Cancer Cells 1991;3:221-6.
8. Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis 1998;24:216-30.
9. Kalthoff H, Roeder C, Brockhaus M, Thiele HG, Schmiegel W. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor α and epidermal growth factor receptor mRNA. J Biol Chem 1993;268:2762-6.
10. Rothe J, Bluethmann H, Gentz R, Lesslauer W, Steinmetz M. Genomic organization and promoter function of the murine tumor necrosis factor receptor β gene. Mol Immunol 1993;30:165-75.
11. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392-9.
12. Barbara JA, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, et al. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptorand p75 receptor-selective TNF-α mutants. EMBO J 1994;13:843-50.
13. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004;63 Suppl 2:ii2-12.
14. Keyser FD, Mielants H, Veys EM. Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2001;2:85-93.
15. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
16. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7.
17. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-α inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann Intern Med 2005;143:918-20.
18. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
19. Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007;25:23-8.
20. Denton CP, Engelhart M, Tvede N, Khan K, Carreira PE, Gonzalez FD, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis [abstract]. Arthritis Rheum 2006;54 Suppl 9:S524.
21. Ellman MH, MacDonald PA, Hayes FA. Etanercept as treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000;43 Suppl 9:S392.
22. Ellman MH, MacDonald PA, Katz RS. Open label use of etanercept in eight scleroderma patients [abstract]. Ann Rheum Dis 2003;62 Supp I:229.
23. Allanore Y, Devos-Francois G, Caramella C, Boumier P, Jounieaux V, Kahan A. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006;65:834-5.
24. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004;329:1266.
25. Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP. Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988;236:47-52.
26. Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, et al. Comparative effects of interleukin-1 and tumor necrosis factor-α on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts. J Invest Dermatol 1991;96:243-9.
27. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor α. Arthritis Rheum 2003;48:2593-604.
28. Kouba DJ, Chung KY, Nishiyama T, Vindevoghel L, Kon A, Klement JF, et al. Nuclear factor-κB mediates TNF-α inhibitory effect on α2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 1999;162:4226-34.
29. Verrecchia F, Wagner EF, Mauviel A. Distinct involvement of the Jun-N-terminal kinase and NF-κB pathways in the repression of the human COL1A2 gene by TNF-α. EMBO Rep 2002;3:1069-74.
30. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-α inhibits transforming growth factor-β/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226-31.
31. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
32. Meikle MC, Atkinson SJ, Ward RV, Murphy G, Reynolds JJ. Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interleukin 1: evidence that breakdown is mediated by metalloproteinases. J Periodontal Res 1989;24:207-13.
33. Ito A, Sato T, Iga T, Mori Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett 1990;269:93-5.
34. Armendariz-Borunda J, Katayama K, Seyer JM. Transcriptional mechanisms of type I collagen gene expression are differentially regulated by interleukin-1β, tumor necrosis factor α, and transforming growth factor β in Ito cells. J Biol Chem 1992;267:14316-21.
35. Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF) α increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 2005;280:36099-109.
36. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-α induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 2005;32:342-9.
37. McCulloch CA, Knowles GC. Deficiencies in collagen phagocytosis by human fibroblasts in vitro: a mechanism for fibrosis? J Cell Physiol 1993;155:461-71.
38. Chou DH, Lee W, McCulloch CA. TNF-α inactivation of collagen receptors: implications for fibroblast function and fibrosis. J Immunol 1996;156:4354-62.
39. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, et al. Transfer of tumor necrosis factor-α to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-β1 and myofibroblasts. Am J Pathol 1998;153:825-32.
40. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007;179:2592-9.
41. Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis: a mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96:250-9.
42. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 1997;81:627-35.
43. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci U S A 2000;97:12746-51.
44. Piguet PF, Grau GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 1990;136:103-10.
45. Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ. Overexpression of tumor necrosis factor-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β. Am J Respir Cell Mol Biol 2003;29:669-76.
46. Buck M, Houglum K, Chojkier M. Tumor necrosis factor-α inhibits collagen α1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol 1996;149:195-204.
47. 1(I) gene expression through a tissue-specific regulatory region. Am J Physiol 1998;274:G840-7.
48. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990;344:245-7.
49. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-8.
50. Farivar AS, Mackinnon-Patterson B, McCourtie AS, Namkung J, Ward PA, Mulligan MS. Obliterative airway disease in rat tracheal allografts requires tumor necrosis factor α. Exp Mol Pathol 2005;78:190-7.
51. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD. Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005;67:1812-20.
52. Liu JY, Brass DM, Hoyle GW, Brody AR. TNF-α receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am J Pathol 1998;153:1839-47.
53. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998;24:721-43.
54. Ortiz LA, Lasky J, Lungarella G, Cavarra E, Martorana P, Banks WA, et al. Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999;20:825-33.
55. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999;277:F766-72.
56. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S. Contributions of angiotensin II and tumor necrosis factor-α to the development of renal fibrosis. Am J Physiol Renal Physiol 2001;280:F777-85.
57. Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest 2002;82:571-83.
58. Sudo K, Yamada Y, Moriwaki H, Saito K, Seishima M. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. Cytokine 2005;29:236-44.
59. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006;55:415-24.